Nomura S, Hanaki H, Unemi N
Antibiotic Research Group, Anticancer and Antimicrobial Research Laboratory, Taiho Pharmaceutical Company, Tokushima, Japan.
Chemotherapy. 1996 Jul-Aug;42(4):253-8. doi: 10.1159/000239452.
The in vitro activity of TOC-50, a new parenteral cephalosporin, was assessed against methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE). TOC-50 showed excellent activity, which was stronger than that of methicillin, cloxacillin, the cephalosporins tested, imipenem, gentamycin, minocycline, ofloxacin and ciprofloxacin against MRSA and had a minimum inhibitory concentration (MIC) comparable to that of vancomycin (the MICs of TOC-50 and vancomycin for growth inhibition of 90% of the strains tested were 3.13 and 1.56 micrograms/ml, respectively). Against MRSE, TOC-50 exhibited excellent activity, which was stronger than that of methicillin, ampicillin, the cephalosporins tested and imipenem, and was twice as active as vancomycin. In terms of the bactericidal effect against MRSA, TOC-50 was superior to vancomycin.
对一种新型肠外头孢菌素TOC - 50针对耐甲氧西林金黄色葡萄球菌（MRSA）和表皮葡萄球菌（MRSE）的体外活性进行了评估。TOC - 50表现出优异的活性，其对MRSA的活性强于甲氧西林、氯唑西林、所测试的头孢菌素、亚胺培南、庆大霉素、米诺环素、氧氟沙星和环丙沙星，且其最低抑菌浓度（MIC）与万古霉素相当（TOC - 50和万古霉素对90%受试菌株生长抑制的MIC分别为3.13和1.56微克/毫升）。针对MRSE，TOC - 50表现出优异的活性，强于甲氧西林、氨苄西林、所测试的头孢菌素和亚胺培南，且活性是万古霉素的两倍。在对MRSA的杀菌效果方面，TOC - 50优于万古霉素。
